NewSpring Capital led the undisclosed equity financing behind the merger of Kincell Bio and Cellipont Bioservices, forming Kincellis Advanced Therapies, a US-based CDMO focused on cell therapies and advanced modalities. Existing investors Kineticos Life Sciences, Health Quest Capital and Great Point Partners also supported the equity financing, alongside a debt facility from JP Morgan.

Kincellis combines Kincell's immune-cell expertise with Cellipont's experience across stem cells, iPSCs, MSCs, dendritic cells, exosomes and mRNA-enabled approaches, supporting autologous and allogeneic therapies. Together, the companies have released more than 150 GMP batches and are supporting 10 IND filings this year.

The combined company operates approximately 140,000 square feet across Gainesville, Florida; Research Triangle Park, North Carolina; and The Woodlands, Texas, spanning 16 GMP manufacturing suites with more than 200 team members.

William Blair & Company advised Cellipont Bioservices. Financial terms were not disclosed.